NCT06195683View on ClinicalTrials.gov

Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

June 20, 2025

Conditions

Non-small Cell Lung CancerPDL1 Gene Mutation

Interventions

DRUG

Serplulimab

Serplulimab for 4.5mg/kg IV Q3W day 1,22,43,64

Trial Locations (1)

310000

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

Zhejiang Cancer Hospital

OTHER

NCT06195683 - Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study. | Biotech Hunter | Biotech Hunter